Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: hI-con1; hIcon1; human Immuno-conjugate 1; ICON-1; Immuno-conjugate-1

Latest Information Update: 28 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer Iconic Therapeutics; Yale University
  • Class Antineoplastics; Drug conjugates; Eye disorder therapies; Immunoconjugates; Immunoproteins; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; Natural killer cell stimulants; Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Research Solid tumours
  • No development reported Cancer; Uveal melanoma

Most Recent Events

  • 28 Jun 2019 No recent reports of development identified for phase-I development in Uveal-melanoma in USA (Intravitreous)
  • 26 Mar 2018 Phase-II clinical trials in Wet age-related macular degeneration (Combination therapy, In the elderly, In adults) in USA (Intravitreous) (NCT03452527)
  • 02 Mar 2018 Iconic Therapeutics plans an open label phase II trial for Wet age-related macular degeneration (Maintenance or Combination therapy, In the elderly, In adults) in USA (Intravitreous) (NCT03452527)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top